Novel imaging biomarker identifies mitochondrial dysfunction in PD

Imaging with 31-phosphorus magnetic resonance spectroscopy (31P-MRS) shows promise as a tool for identifying patients with Parkinson’s disease (PD) who have significant mitochondrial dysfunction, according to new findings presented at the MDS 2021 virtual congress.

The heterogeneity of pathogenic mechanisms implicated in PD can explain treatment failures. Being able to identify patients with mitochondrial dysfunction as a dominant pathogenic mechanism (it has been implicated in both familial and sporadic PD) could lead to more effective clinical trials and pave the way for more personalized care with precision medicine.